Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|The Lancet Neurology|2012Cited by 606
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosisLisa F. Barcellos, Jorge R. Oksenberg, Stephen Sawcer et al.|Human Molecular Genetics|2006Cited by 313
Negligible impact of rare autoimmune-locus coding-region variants on missing heritabilityKaren A. Hunt, David A. van Heel, Oliver S. Burren et al.|Nature|2013Cited by 189
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|Trials|2011Cited by 119